000250 — Sam Chun Dang Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual income statement for Sam Chun Dang Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	186,602	166,862	167,275	177,335	192,669
Cost of Revenue
Gross Profit	110,656	94,000	83,078	89,995	96,966
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	162,932	161,843	183,057	165,111	184,154
Operating Profit	23,670	5,019	-15,782	12,225	8,514
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	19,317	16,581	-19,549	8,920	-4,549
Provision for Income Taxes
Net Income After Taxes	19,600	7,495	-10,361	8,832	-4,188
Minority Interest
Net Income Before Extraordinary Items
Net Income	10,452	-966	-16,555	5,838	-10,383
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10,452	-966	-16,555	5,838	-10,383
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	538	-33.7	-737	229	-441
Dividends per Share